Monitor upcoming catalysts including the sBLA submission for zanidatamab in 1L GEA and the launch of Modeyso, while watching for margin pressure from increased R&D and SG&A expenses.
Price Chart
Executive Summary
Jazz Pharmaceuticals reported strong 2025 financial results with $4.3 billion in revenue (+5% YoY) and $1.2 billion in 4Q25 (+10% YoY), driven by Xywav and Epidiolex growth. The company provided 2026 revenue guidance of $4.25-$4.5 billion and highlighted key pipeline progress, including the expected sBLA submission for zanidatamab in 1L GEA.
Key Financial Metrics
Key Facts
- Total revenue was $4.3 billion in 2025 (+5% YoY) and $1.2 billion in 4Q25 (+10% YoY)
- Xywav revenue was $1.7 billion (+12% YoY) and Epidiolex revenue was $1.1 billion (+9% YoY)
- 2026 revenue guidance is $4.25-$4.5 billion
- Non-GAAP adjusted EPS was $8.38 in 2025, down from $20.65 in 2024
- Company expects to submit sBLA for zanidatamab in 1L GEA in 1Q26
Financial Impact
$4.3 billion in 2025 revenue, $1.2 billion in 4Q25 revenue, $4.25-$4.5 billion 2026 guidance
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Xywav | $1.7B | +12.0% |
| Epidiolex | $1.1B | +9.0% |
| Zepzelca | $307.3M | -4.0% |
Risk Factors
- Non-GAAP adjusted EPS declined significantly from 2024 to 2025
- Increased R&D and SG&A expenses could pressure margins
- Dependence on key products Xywav and Epidiolex for revenue growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001232524-26-000012 |
| Document: jazz-20260224.htm | 0001232524-26-000012 |
| Document: 0001232524-26-000012-index-headers.html | 0001232524-26-000012 |
| Document: 0001232524-26-000012-index.html | 0001232524-26-000012 |
| Document: 0001232524-26-000012.txt | 0001232524-26-000012 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | Press Release | $213.76 $211.97 | ▼ −0.84% | ▼ −1.36% | $210.99 (−1.30%) |
Oct 9, 2026 17d ago | 8-K | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 8, 2026 17d ago | 144 | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 6, 2026 19d ago | 144 | $231.19 $222.45 | ▼ −3.78% | ▼ −3.36% | $210.99 (−8.74%) |
Oct 1, 2026 24d ago | 144 | $235.67 $236.04 | ▲ +0.16% | ▼ −0.52% | $210.99 (−10.47%) |
Sep 15, 2026 5w ago | 8-K | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 14, 2026 5w ago | Insider Cluster | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 10, 2026 6w ago | Insider Cluster | $245.80 $245.87 | ▲ +0.03% | ▲ +0.47% | $210.99 (−14.16%) |
Sep 2, 2026 7w ago | Insider Cluster | $247.57 $246.81 | ▲ +0.30% | ▼ −0.08% | $210.99 (+14.78%) |
Aug 31, 2026 7w ago | 144 | $243.71 $245.57 | ▲ +0.76% | ▲ +0.32% | $210.99 (−13.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers